The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.

More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...

Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI ...

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...